Qing Zhou
About
Qing Zhou is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research.
According to data from OpenAlex, Qing Zhou has authored 288 papers receiving a total of 7.1k indexed citations (citations by other indexed papers that have themselves been cited), including 209 papers in Pulmonary and Respiratory Medicine, 169 papers in Oncology and 59 papers in Cancer Research. Recurrent topics in Qing Zhou's work include Lung Cancer Treatments and Mutations (194 papers), Lung Cancer Research Studies (65 papers) and Lung Cancer Diagnosis and Treatment (54 papers). Qing Zhou is often cited by papers focused on Lung Cancer Treatments and Mutations (194 papers), Lung Cancer Research Studies (65 papers) and Lung Cancer Diagnosis and Treatment (54 papers). Qing Zhou collaborates with scholars based in China, United States and Hong Kong. Qing Zhou's co-authors include Yi‐Long Wu, Wen‐Zhao Zhong, Jin‐Ji Yang, Xu‐Chao Zhang, Jian Su, Hong‐Hong Yan, Hai‐Yan Tu, Chong‐Rui Xu, Zhi Xie and Xue‐Ning Yang and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.
In The Last Decade
Qing Zhou
262 papers receiving 7.0k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Qing Zhou China | 43 | 4.9k | 4.3k | 1.9k | 1.8k | 560 | 288 | 7.1k | ||
| Lyudmila Bazhenova United States | 38 | 3.8k 0.8× | 4.5k 1.0× | 2.0k 1.0× | 2.1k 1.2× | 713 1.3× | 169 | 7.1k | ||
| Antonio Chella Italy | 39 | 3.5k 0.7× | 2.9k 0.7× | 1.6k 0.8× | 1.2k 0.7× | 260 0.5× | 130 | 5.5k | ||
| Hyo Sup Shim South Korea | 37 | 3.1k 0.6× | 2.4k 0.5× | 1.5k 0.8× | 1.1k 0.6× | 393 0.7× | 164 | 5.1k | ||
| Antonio Marchetti Italy | 36 | 2.9k 0.6× | 2.7k 0.6× | 2.5k 1.3× | 2.0k 1.1× | 263 0.5× | 111 | 5.8k | ||
| Wen‐Zhao Zhong China | 40 | 4.5k 0.9× | 3.7k 0.9× | 1.3k 0.7× | 1.4k 0.8× | 472 0.8× | 231 | 6.1k | ||
| Umberto Malapelle Italy | 43 | 2.8k 0.6× | 2.6k 0.6× | 2.1k 1.1× | 2.4k 1.4× | 234 0.4× | 265 | 5.7k | ||
| Yoon‐La Choi South Korea | 51 | 4.0k 0.8× | 3.9k 0.9× | 2.8k 1.5× | 2.0k 1.1× | 414 0.7× | 288 | 8.3k | ||
| Haiquan Chen China | 47 | 4.9k 1.0× | 2.9k 0.7× | 2.0k 1.0× | 1.5k 0.8× | 409 0.7× | 236 | 7.6k | ||
| Fernando López‐Ríos Spain | 44 | 2.7k 0.6× | 3.2k 0.7× | 2.1k 1.1× | 1.8k 1.0× | 373 0.7× | 177 | 6.4k | ||
| Noriko Motoi Japan | 32 | 3.3k 0.7× | 2.6k 0.6× | 1.4k 0.7× | 931 0.5× | 404 0.7× | 191 | 5.7k |
Countries citing papers authored by Qing Zhou
Since
Specialization
Citations
This map shows the geographic impact of Qing Zhou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Qing Zhou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Qing Zhou more than expected).
Fields of papers citing papers by Qing Zhou
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Qing Zhou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Qing Zhou. The network helps show where Qing Zhou may publish in the future.
Co-authorship network of co-authors of Qing Zhou
This figure shows the co-authorship network connecting the top 25 collaborators of Qing Zhou. A scholar is included among the top collaborators of Qing Zhou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Qing Zhou. Qing Zhou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Zhou, Qing, Ying Liu, Yijun Liu, et al.. (2024). PLUNC inhibits invasion and metastasis in nasopharyngeal carcinoma by inhibiting NLRP3 inflammasome activation. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1870(7). 167352–167352.
2.
Zheng, Mei-Mei, Qing Zhou, Ben‐Yuan Jiang, et al.. (2024). Cerebrospinal fluid circulating tumour DNA profiling for risk stratification and matched treatment for central nervous system metastases of NSCLCM metastases of NSCLC. 5. 100175–100175.
3.
Dai, Shipeng, et al.. (2024). miR-122/NEGR1 axis contributes colorectal cancer liver metastasis by PI3K/AKT pathway and macrophage modulation. Journal of Translational Medicine. 22(1). 1060–1060.
4.
Wei, Xue‐Wu, Xue Fan, Chong‐Rui Xu, et al.. (2024). Redox high phenotype mediated by KEAP1/STK11/SMARCA4/NRF2 mutations diminishes tissue-resident memory CD8+ T cells and attenuates the efficacy of immunotherapy in lung adenocarcinoma. OncoImmunology. 13(1). 2340154–2340154.
5.
Huang, Kai, Dan Pu, Ting Mei, et al.. (2024). Neoadjuvant chemoimmunotherapy in patients with limited-stage small cell lung cancer: A retrospective study.. Journal of Clinical Oncology. 42(16_suppl). e20002–e20002.
6.
Zhou, Qing, Lin Wu, Bo Jiang, et al.. (2023). Uliledlimab and toripalimab combination therapy in treatment naive advanced NSCLC: Phase 1b/2 clinical trial results using CD73 as a potential predictive biomarker.. Journal of Clinical Oncology. 41(16_suppl). 2570–2570.
7.
Wu, Yi‐Long, Qing Zhou, Jie Wang, et al.. (2023). Randomized phase 3 study of first-line AZD3759 (zorifertinib) versus gefitinib or erlotinib in EGFR-mutant ( EGFR m + ) non–small-cell lung cancer (NSCLC) with central nervous system (CNS) metastasis.. Journal of Clinical Oncology. 41(16_suppl). 9001–9001.
8.
Deng, Jie, Hong‐Hong Yan, Ming‐Yu Yang, et al.. (2023). WS02.13 PD-L1 Expression Guidance on Sintilimab versus Pembrolizumab in Untreated Advanced NSCLC (CTONG1901). Journal of Thoracic Oncology. 18(11). S38–S39.
9.
Zhou, Qing, Yi‐Long Wu, Jianping Li, et al.. (2023). 658MO Phase I study of SHR-A2009, a HER3-targeted ADC, in advanced solid tumors. Annals of Oncology. 34. S463–S463.
10.
Zhou, Qing, et al.. (2023). [Early Onset Pulmonary Events and Management Strategies during the Treatment of
ALK Positive NSCLC Patients with Brigatinib].. SHILAP Revista de lepidopterología. 26(4). 281–290.
11.
Zhao, Jun, Xinmin Yu, Dingzhi Huang, et al.. (2023). SAFFRON-103: a phase 1b study of the safety and efficacy of sitravatinib combined with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancer. Journal for ImmunoTherapy of Cancer. 11(2). e006055–e006055.
12.
Yang, Lei, Song Dong, Xue‐Wu Wei, et al.. (2022). Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma. Journal for ImmunoTherapy of Cancer. 10(2). e003534–e003534.
13.
Chen, Hsin‐Jen, Ji‐Yuan Zhou, Jun Zhao, et al.. (2021). 32O First-in-human (FIH) study of SCC244, a novel potent and highly selective c- MET inhibitor, in patients (pts) with advanced non-small cell lung cancer (NSCLC). Annals of Oncology. 32. S14–S14.
14.
Cheng, Ying, Yong He, Wěi Li, et al.. (2021). Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study. Targeted Oncology. 16(2). 165–176.
15.
Cheng, Ying, Tony Mok, Xiangdong Zhou, et al.. (2021). Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050). Lung Cancer. 154. 176–185.
16.
Wang, Fen, Feng Jin, Boran Cheng, et al.. (2021). The real-world efficacy and safety of anlotinib in advanced non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology. 148(7). 1721–1735.
17.
Zheng, Mei-Mei, Hai‐Yan Tu, Jin‐Ji Yang, et al.. (2021). Clinical outcomes of non–small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatments. European Journal of Cancer. 150. 23–30.
18.
Zhang, Ming, Xiao Jiang, Songshan Jiang, et al.. (2019). LncRNA FOXD2-AS1 Regulates miR-25-3p/Sema4c Axis To Promote The Invasion And Migration Of Colorectal Cancer Cells. SHILAP Revista de lepidopterología.
19.
Dong, Zhong‐Yi, Wen‐Zhao Zhong, Xu‐Chao Zhang, et al.. (2016). Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma. Clinical Cancer Research. 23(12). 3012–3024.
20.
Yang, Jin-Ji, Xu‐Chao Zhang, Jian Su, et al.. (2014). Lung Cancers with Concomitant EGFR Mutations and ALK Rearrangements: Diverse Responses to EGFR-TKI and Crizotinib in Relation to Diverse Receptors Phosphorylation. Clinical Cancer Research. 20(5). 1383–1392.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Lyudmila Bazhenova Breakdown of academic impact, for papers by Antonio Chella Breakdown of academic impact, for papers by Hyo Sup Shim Breakdown of academic impact, for papers by Antonio Marchetti Breakdown of academic impact, for papers by Wen‐Zhao Zhong Breakdown of academic impact, for papers by Umberto Malapelle Breakdown of academic impact, for papers by Yoon‐La Choi Breakdown of academic impact, for papers by Haiquan Chen Breakdown of academic impact, for papers by Fernando López‐Ríos Breakdown of academic impact, for papers by Noriko Motoi